[go: up one dir, main page]

PL3458448T3 - Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby - Google Patents

Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby

Info

Publication number
PL3458448T3
PL3458448T3 PL17790287T PL17790287T PL3458448T3 PL 3458448 T3 PL3458448 T3 PL 3458448T3 PL 17790287 T PL17790287 T PL 17790287T PL 17790287 T PL17790287 T PL 17790287T PL 3458448 T3 PL3458448 T3 PL 3458448T3
Authority
PL
Poland
Prior art keywords
alcoholic steatohepatitis
treating non
fasn inhibitors
fasn
inhibitors
Prior art date
Application number
PL17790287T
Other languages
English (en)
Inventor
David S. MILLAN
Wei Lu
Sailaja Battula
Stephane Soroosh Radfar
Seng-Lai TAN
Original Assignee
Forma Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forma Therapeutics, Inc. filed Critical Forma Therapeutics, Inc.
Publication of PL3458448T3 publication Critical patent/PL3458448T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL17790287T 2016-04-25 2017-04-25 Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby PL3458448T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662327167P 2016-04-25 2016-04-25
EP17790287.1A EP3458448B1 (en) 2016-04-25 2017-04-25 Fasn inhibitors for use in treating non-alcoholic steatohepatitis
PCT/US2017/029469 WO2017189613A1 (en) 2016-04-25 2017-04-25 Methods of using fasn inhibitors

Publications (1)

Publication Number Publication Date
PL3458448T3 true PL3458448T3 (pl) 2021-12-06

Family

ID=60157111

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17790287T PL3458448T3 (pl) 2016-04-25 2017-04-25 Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby

Country Status (9)

Country Link
US (2) US20170312273A1 (pl)
EP (1) EP3458448B1 (pl)
DK (1) DK3458448T3 (pl)
ES (1) ES2886935T3 (pl)
MA (1) MA45047A (pl)
PL (1) PL3458448T3 (pl)
PT (1) PT3458448T (pl)
TW (1) TW201737943A (pl)
WO (1) WO2017189613A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191366A (en) 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
JP7300394B2 (ja) 2017-01-17 2023-06-29 ヘパリジェニックス ゲーエムベーハー 肝再生の促進又は肝細胞死の低減もしくは予防のためのプロテインキナーゼ阻害
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
WO2020092376A1 (en) * 2018-10-29 2020-05-07 Forma Therapeutics, Inc. Treating non-alcoholic steatohepatitis (nash)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN113265468B (zh) * 2021-07-21 2021-10-12 北京大学第三医院（北京大学第三临床医学院） 一种与宫颈癌诊断、治疗和预后相关的miRNA
US20250166821A1 (en) * 2021-11-11 2025-05-22 Sagimet Biosciences Inc. Methods for prediction of treatment response in non-alcoholic fatty liver disease
EP4442692A4 (en) * 2021-11-29 2025-10-01 Ocean Univ China IMIDAZOTHIAZOLE DERIVATIVE, PROCESS FOR ITS PREPARATION AND USE

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US20090162870A1 (en) * 2007-02-27 2009-06-25 Fasgen Diagnostics, Llc Fatty acid synthase in liver disease
MY191366A (en) * 2013-03-13 2022-06-20 Forma Therapeutics Inc Novel compounds and compositions for inhibition of fasn
WO2014146747A1 (en) 2013-03-21 2014-09-25 Merck Patent Gmbh Piperazine derivatives as fasn inhibitors
EP3077387B1 (en) * 2013-12-03 2017-12-20 Janssen Pharmaceutica NV Benzamide derivative useful as fasn inhibitors for the treatment of cancer
EP3083600B1 (en) * 2013-12-17 2018-09-26 Janssen Pharmaceutica NV Imidazolin-5-one derivatives useful as fasn inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
WO2017189613A1 (en) 2017-11-02
DK3458448T3 (da) 2021-08-23
US20170312273A1 (en) 2017-11-02
EP3458448B1 (en) 2021-06-23
EP3458448A1 (en) 2019-03-27
TW201737943A (zh) 2017-11-01
MA45047A (fr) 2019-03-27
EP3458448A4 (en) 2019-04-17
ES2886935T3 (es) 2021-12-21
PT3458448T (pt) 2021-09-10
US20190374536A1 (en) 2019-12-12

Similar Documents

Publication Publication Date Title
SG11201507288UA (en) Compositions and methods for treating non-alcoholic steatohepatitis
IL272596A (en) Pridopidine for use in the treatment of ALS
IL256874B (en) Immune checkpoint suppressors for use in the treatment of blood-borne cancers
IL256056A (en) ezh2 inhibitors for the treatment of lymphoma
PL3458448T3 (pl) Inhibitory fasn do zastosowania w leczeniu niealkoholowego stłuszczeniowego zapalenia wątroby
EP3054940A4 (en) Compositions and methods for treating non-alcoholic steatohepatitis
GB201605126D0 (en) Inhibitors and their uses
IL259992B (en) Compounds for use in methods for treating increased sensitivity to pain
IL275002A (en) Fatty acid antecedents for the treatment of nonalcoholic fatty liver disease
IL278247B (en) mct4 inhibitors to treat the disease
IL272088A (en) A DHODH inhibitor for use in the treatment of hematological cancer
SG11201708027XA (en) Compounds and their use as bace1 inhibitors
IL271020A (en) Tinostemustine for the treatment of sarcoma
HUE049600T2 (hu) GLS1 inhibitorok betegségek kezelésére
GB201702160D0 (en) Inhibitors for use in therapy
IL265139B (en) Dopamine-b-hydroxylase inhibitors
IL254916A0 (en) Inhibitors and their uses
IL258870A (en) Substituted indazole compounds as rorgammat inhibitors and uses thereof
GB201612860D0 (en) Inhibitors
SI3331610T1 (sl) Sredstva za uporabo pri zdravljenju gliomov
PL2949399T3 (pl) Urządzenie do obróbki artykułów drewnianych
IL259817A (en) vap-1 inhibitors for pain management
IL271236A (en) Licofligozin for the treatment of non-alcoholic steatohepatitis
PL3093022T3 (pl) Inhibitory gata-3 do zastosowania do leczenia astmy powodowanej przez th2
IL283687A (en) usp19 inhibitors and their use for therapeutic purposes